Ecopia Begins Patient Dosing in Cancer Trial
Posted on: Friday, 7 April 2006, 15:01 CDT
Quebec firm Ecopia BioSciences has began dosing its first patient in a phase I clinical trial of its anticancer product candidate ECO-4601.
The phase I study is designed to test the safety and tolerability of ECO-4601. Up to 30 patients suffering from one of six types of cancer, and who are refractory to current chemotherapies, will be recruited for this trial. Such cancers include glioblastomas, breast, prostate, ovarian, lung and colon cancers.
The clinical trial involves a 21-day cycle during which escalating dosages of the compound will be tested in different patients via continuous infusion using ambulatory pumps for 14 days, followed by a seven-day rest.
The investigation is taking place at the clinical research unit of the Sir Mortimer B. Davis - Jewish General Hospital (JGH), a McGill University Teaching Hospital.
ECO-4601 is a novel small molecule that crosses the blood brain barrier and is effective in significantly inhibiting primary brain tumor growth and other types of cancers. Just like well-known chemotherapies such as doxorubicin and mitomycin C, ECO-4601 comes from microorganisms that live in common soil.
However, unlike these drugs that were discovered many decades ago, ECO-4601 represents a new chemical class, which, according to Ecopia, is the fruit of a very unique drug discovery platform called the Decipher technology.
Source: Datamonitor
Related Articles
- NCI Renews Mayo Clinic Cancer Center Support Grant, Extends Comprehensive Status
- Rexinoid Developed By NuRx Pharmaceuticals Shows Promise in Prevention, Treatment of Lung, Breast Cancer, Paper in Clinical Cancer Research Reports
- Enzon's PEG-SN38 Featured in Clinical Cancer Research
- Novacea's Proof-of-Principle Study of AQ4N in Solid Tumors Published in Clinical Cancer Research
- Thallion Announces Positive Safety and Efficacy Data From ECO-4601 Phase I/II Trial
- Thallion to Present Positive ECO-4601 Clinical and Non-Clinical Data at Two Conferences in November
- Thallion to Present ECO-4601 Human Pharmacokinetic Data at AACR-NCI-EORTC Conference
- Clinical Cancer Research Publishes Paper Comparing CTCs to Imaging in Predicting Overall Survival in Metastatic Breast Cancer
- Application of Sentinel Principle in Bladder Cancer Published in Clinical Cancer Research
- Ecopia Announces Filing of Clinical Trial Application for ECO-4601
 |
 |
User Comments (0)
RSS Feeds